These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 202354)

  • 1. [Immunogenicity and thymus-dependence of the polymerized alpha-toxoid of Clostridium perfringens].
    Petrov RV; Shemanova GF; Kaverzneva ED; Kissel' VL; Panteleev EI
    Biull Eksp Biol Med; 1977 Dec; 84(12):695-8. PubMed ID: 202354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Factors modulating production of antibodies against Clostridium perfringens in mammals].
    Shemanova GF; Sergeeva TI; Panteleev EI; Vlasova EV; Dmitrieva LN
    Biull Eksp Biol Med; 1981 Sep; 92(9):322-5. PubMed ID: 6271303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study on the immunogenic properties of Clostridium perfringens type A toxoid.
    Shemanova GF; Vlasova EV; Dmitrieva LN; Trapezov EV; Gorbacheva LD
    J Hyg Epidemiol Microbiol Immunol; 1986; 30(3):323-9. PubMed ID: 2877025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha toxoid of Clostridium perfringens. II. Immunogenicity of the toxoid.
    Ito A
    Jpn J Med Sci Biol; 1970 Feb; 23(1):21-30. PubMed ID: 4317538
    [No Abstract]   [Full Text] [Related]  

  • 5. [Homogeneous Cl. perfringens alpha-anatoxin: its physicochemical and immunogenic properties].
    Shemanova GF; Petrov RV; Dmitrieva LN; Panteleev EI; Drachev VA
    Zh Mikrobiol Epidemiol Immunobiol; 1978 May; (5):117-22. PubMed ID: 208330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preparation and evaluation of immunogenic properties of Clostridium perfringens type A toxoid].
    Rymkiewicz D; Sawicki J; Brühl A; Sochańska R
    Med Dosw Mikrobiol; 1979; 31(2):95-102. PubMed ID: 228130
    [No Abstract]   [Full Text] [Related]  

  • 7. The detection of the factor lowering the immunogenicity of toxoid of Clostridium perfringens type A.
    Shemanova GF; Vlasova EV; Sergeeva TI; Panteleyev EI
    Arch Roum Pathol Exp Microbiol; 1981; 40(4):299-303. PubMed ID: 6280638
    [No Abstract]   [Full Text] [Related]  

  • 8. [Properties of C1. perfringens toxoids obtained from purified toxins].
    Dmitrieva LN; Shemanova GF; Vlasova EV; Akhundova KA
    Zh Mikrobiol Epidemiol Immunobiol; 1977 Apr; (4):110-4. PubMed ID: 868405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Recombinant Probiotic, Lactobacillus casei, Expressing the Clostridium perfringens α-toxoid, as an Orally Vaccine Candidate Against Gas Gangrene and Necrotic Enteritis.
    Alimolaei M; Golchin M; Abshenas J; Ezatkhah M; Bafti MS
    Probiotics Antimicrob Proteins; 2018 Jun; 10(2):251-257. PubMed ID: 28401477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The functional activity of wound mononuclear phagocytosing cells in revaccination with a Clostridium perfringens anatoxin].
    Sergeeva TI; Zaĭtseva LG; Chirikova EV; Vasil'eva EI; Babaĭtseva VA; Kornienko OIu
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (6):63-5. PubMed ID: 7879544
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunogenic properties of Clostridium perfringens type A anatheta-hemolysin].
    Sergeeva TI; Dolgikh MS; Blagoveshchenskiĭ VA
    Zh Mikrobiol Epidemiol Immunobiol; 1981 Nov; (11):71-5. PubMed ID: 6275640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Protective properties of theta-hemolysin obtained by affinity chromatography].
    Efimova MG; Blagoveshchenskiĭ VA; Khatuntseva BV
    Zh Mikrobiol Epidemiol Immunobiol; 1982 Dec; (12):87-92. PubMed ID: 6297191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The experimental validation of methods for the emergency immunoprophylaxis of gas gangrene].
    Sergeeva TI; Chirikova EV; Babaĭtseva VA
    Zh Mikrobiol Epidemiol Immunobiol; 1995; (5):9-13. PubMed ID: 8525744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the interrelationship between the content of immunizing units and the immunogenicity of C1. perfringens anatoxins].
    Nenashev VP; Akhundova KA
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Aug; (8):93-6. PubMed ID: 173119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevention of experimental Clostridium novyi and Cl. perfringens gas gangrene in high-velocity missile wounds by active immunisation.
    Boyd NA; Thomson RO; Walker PD
    J Med Microbiol; 1972 Nov; 5(4):467-72. PubMed ID: 4345766
    [No Abstract]   [Full Text] [Related]  

  • 16. [Immunization against gas gangrene and tetanus with sexta-anatoxin (in experiments with animals)].
    Vlasova EV; Larina IA
    Zh Mikrobiol Epidemiol Immunobiol; 1969 Jul; 46(7):113-6. PubMed ID: 4315881
    [No Abstract]   [Full Text] [Related]  

  • 17. [Creation and study of immune antigangrene preparations].
    Papko GF; Sergeeva TI; Rudnitskaia MZ; Egorov VM; Babaĭtseva VA
    Gematol Transfuziol; 1987 Jul; 32(7):20-3. PubMed ID: 2444487
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effectiveness of gas gangrene anatoxins in revaccination by the aerosol method].
    Gefen NE; Egorova NB; Miroshnichenko IV; Efremova VN; Serdtsev AI
    Voen Med Zh; 1975 Feb; (2):47-8. PubMed ID: 166512
    [No Abstract]   [Full Text] [Related]  

  • 19. [Method of determinating the protective capacity of C1. perfringens toxoid].
    Akhundova KA; Nenashev VP
    Zh Mikrobiol Epidemiol Immunobiol; 1975 Apr; (4):43-7. PubMed ID: 176851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics of the immunologic response of animals to Clostridium perfringens anatoxin].
    Petrov RV; Shemanova GF; Panteleev EI; Dmitrieva LN; Vlasova EV
    Zh Mikrobiol Epidemiol Immunobiol; 1977 May; (5):71-4. PubMed ID: 197752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.